Fanny Joubert

AstraZeneca (United Kingdom)

Papers

1

Total Citations

54

H-Index

1

About

Fanny Joubert is a leading researcher in the field of nanomedicine and drug delivery, with a particular focus on dendrimer-based platforms for nucleic acid therapeutics. Her major contributions center on the precise engineering of dendrimer surface chemistry to overcome biological barriers, especially for the cytosolic delivery of mRNA. In her most-cited work (2023, 54 citations), Joubert demonstrated how systematic end-group modifications on PAMAM and poly(L-lysine) dendrimers can dramatically enhance mRNA transfection efficiency, offering a tunable strategy for improving the stability and intracellular release of genetic payloads. This research addresses a critical bottleneck in non-viral gene therapy: achieving efficient endosomal escape without toxicity. Her work has significant implications for the development of next-generation vaccines and RNA-based treatments. Joubert’s precise, structure-activity relationship approach has positioned her as a key innovator in dendrimer chemistry, bridging fundamental materials science with translational medicine. Her findings are widely cited by groups working on polymeric carriers for gene editing and immunotherapy, underscoring her impact on the design of safer, more effective delivery systems.

Research Focus

Key Achievements

1
H-Index
1
Papers
54
Total Citations
54
Avg Citations/Paper
🏆 Most Cited Paper
Precise and systematic end group chemistry modifications on PAMAM and poly(l-lysine) dendrimers to improve cytosolic delivery of mRNA
54 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: AstraZeneca (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago